Evaxion Biotech A/S (EVAX)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 2.47 |
Market Cap | 791.15K |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -14 |
PE Ratio (ttm) | -0.18 |
Forward PE | n/a |
Analyst | Buy |
Ask | 2.68 |
Volume | 1,463,321 |
Avg. Volume (20D) | 2,376,057 |
Open | 2.61 |
Previous Close | 2.61 |
Day's Range | 2.43 - 2.79 |
52-Week Range | 2.22 - 22.50 |
Beta | undefined |
About EVAX
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various...
Analyst Forecast
According to 3 analyst ratings, the average rating for EVAX stock is "Buy." The 12-month stock price forecast is $14, which is an increase of 454.46% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription